

# 東邦大学学術リポジトリ

Toho University Academic Repository

タイトル	Professor Special Lecture: 151st Regular Meeting of the Medical Society of Toho University Concept, Assessment, and Management of Disease Activity in Rheumatoid Arthritis
作成者（著者）	Hideto, Kameda
公開者	The Medical Society of Toho University
発行日	2018.06.01
ISSN	21891990
掲載情報	Toho Journal of Medicine. 4(2). p.43 48.
資料種別	学術雑誌論文
内容記述	REVIEW ARTICLE
著者版フラグ	publisher
JaLCDOI	info:doi/10.14994/tohojmed.2018 009
メタデータのURL	<a href="https://mylibrary.toho u.ac.jp/webopac/TD52616884">https://mylibrary.toho u.ac.jp/webopac/TD52616884</a>

Review Article

# Concept, Assessment, and Management of Disease Activity in Rheumatoid Arthritis

Hideto Kameda

Professor, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University (Ohashi Medical Center)

---

**ABSTRACT:** As a concept, disease activity should be time-differentiated organ damage, and high disease activity should be associated with the high-speed progression of organ damage, mainly joint destruction in rheumatoid arthritis. This concept has been validated by the retrospective analyses of joint destruction during given periods: time-integrated disease activity correlated well with joint destruction. A mathematical description of disease activity as time-differentiated organ damage indicated a new concept, “negative activity,” which means the improvement of organ damage, and it should be clearly distinguished from “zero activity,” which means neither worsening nor improvement of organ damage. However, current composite activity measures do not distinguish “negative activity” from “zero activity,” and the correlation of the time-integrated disease activity score to joint destruction during a given period is considerably insufficient. A formula with the modification of Newton’s motion equation indicated the difference between synthetic compounds and biological agents in the importance of patient “capacity.” Thus, the primary objective of the serum trough monitoring of biological agents is to avoid the lack of effectiveness due to underdosing, whereas that of synthetic compounds is to avoid dose-dependent adverse events due to overdosing.

Toho J Med 4 (2): 43–48, 2018

---

**KEYWORDS:** activity, damage, joint destruction, rheumatoid arthritis

## Introduction

Recent advances in the treatment strategy for rheumatoid arthritis (RA) called “treat to target (T2T)”<sup>1)</sup> and the development of biological agents targeting key cytokines such as tumor necrosis factor (TNF) and interleukin-6 have led to favorable outcomes in the majority of

Japanese patients with RA<sup>2)</sup>; even clinical remission was achieved by 50% of patients.<sup>3)</sup> However, pitfalls in the current assessment of the clinical disease activity of RA have been elucidated using high-sensitivity imaging methods such as musculoskeletal ultrasonography (US).<sup>4)</sup> Therefore, we provide a constructive view of the concept, assessment, and management of disease activity in RA for




Fig. 1 Concept of disease activity and its temporal relationship with organ damage.

A. Disease activity as time-differentiated organ damage.

Although the speed of organ damage may be constant (solid straight line) or changing (dotted curves) from  $t_1$  to  $t_2$ , it can be estimated as constant in a very short time interval. The three arrows indicate negative, zero, and positive activity in order from the top.

B. Organ damage as time-integrated disease activity.

The area under the curve of temporal change in disease activity corresponds to organ damage during the time from  $t_1$  to  $t_2$ . Even if the disease activities at times of both  $t_1$  and  $t_2$  are comparable, rapid control of disease activity results in minimal organ damage (area in black), which is much less (the difference shown in gray) than the delayed control of disease activity.

further improvement in the outcome of patients with RA.

### Concept of Disease Activity in RA

Because RA is a systemic inflammatory disease predominantly involving the joint synovium, it is hard to precisely assess disease activity. As a concept, disease activity should be time-differentiated organ damage (Fig. 1). Therefore, high disease activity implies the high-speed progression of organ damage, mainly joint destruction in RA. This concept has been validated by the retrospective analyses of joint destruction during given periods: time-integrated disease activity correlated well with joint destruction.<sup>5-10)</sup> Indeed, these observations led to the T2T strategy to minimize organ damage such as joint destruction by achieving acceptable disease activity, remission or at least low disease activity, as early as possible.<sup>1)</sup>

A mathematical description of disease activity as time-differentiated organ damage indicated a new concept,

“negative activity” (Fig. 1). The conventional concept of disease activity included only “zero activity” and “positive activity,” and remission included “zero activity” and a clinically nonsignificant “positive activity.” However, “zero activity” means neither worsening nor improvement of organ damage, which should be clearly distinguished from “negative activity,” which means the improvement of organ damage. Indeed, a considerable number of patients have shown the repair of joint damage as a whole in recent clinical trials. Therefore, a new T2T strategy should aim at the prevention or repair of organ damage as much as possible by achieving “negative or zero activity” according to the existence of organ damage at the start of RA treatment.

### Assessment of Disease Activity in RA

The validity of the clinical assessment of RA is determined from various aspects: face validity, content validity,

1) Patient's global (0–100 mm VAS)

2) Swollen joint score (0–114)

0: none

1: mild (confirmed only by palpation)

2: moderate (confirmed by inspection)

3: tense

3) Serum C-reactive protein (mg/L)

Summation of 1) - 3)




Fig. 2 Handy rheumatoid activity score with 38 joints (HRAS38). HRAS38 is the sum of the patient's global assessment (0-100 mm visual analogue scale (VAS)), swollen joint score of 38 joints (0-3 for each), and serum C-reactive protein level (mg/dL).

Table 1 Comparison between synthetic compounds and biological agents.

	Synthetic compounds	Biological agents
Molecular weight	<10,000 (MTX 454.4; tofacitinib citrate 504.5)	>10,000 (IgG ~ 150,000)
Cellular localization of the targeted molecule	Intracellular	Extracellular/cellular membrane
Specificity	Insufficient	Sufficient
Dose	Limited dose	Sufficient dose

MTX: methotrexate.

construct validity, criterion validity, and discriminant validity.<sup>11, 12)</sup> As a practical reason, clinical assessment should be feasible.<sup>12)</sup> According to the above criteria, composite disease activity measures have been developed and validated in clinical trials. These include DAS (disease activity score),<sup>13)</sup> DAS28 (28-joint count DAS),<sup>14)</sup> and SDAI (simplified disease activity index).<sup>15)</sup> Although all the above composite activity measures include tender joint count and global assessment by the patient, these parameters have been reported to be poorly correlated with joint destruction evaluated by hand and foot radiographs.<sup>16, 17)</sup> Previously, we developed a new composite RA activity measure, handy rheumatoid activity score with 38 joints (HRAS38), composed of global assessment by the patient, swollen joint score, and serum C-reactive protein level (Fig. 2).<sup>18)</sup> HRAS38 has been validated in 2 clinical trials conducted in Japan<sup>19, 20)</sup>; however, it failed to show major advantages over conventional activity measures (unpublished data and our publication<sup>21)</sup>). Because we have

recently shown again that tender joint count should be excluded from the composite activity measure of RA in a study using joint US as a gold standard,<sup>4)</sup> further improvement in the composite activity measure of RA is awaited.

### Management of Disease Activity in RA

Because inflammatory disease activity is defined as time-differentiated organ damage, namely, the speed of progression of organ damage, the control of disease activity mimics the brake of an automobile. Deceleration of the speed of organ destruction aiming at "negative or zero activity" can be described as a formula with the modification of Newton's motion equation:

$$F = C \cdot (-d^2x/dt^2)$$

where F is the intensity of treatment (ex. dosage), C is the capacity of the patient (ex. body mass, age, renal function), and  $-d^2x/dt^2$  is the deceleration rate of disease activity (x: organ damage; t: time).

The above formula indicates the difference in the importance of “capacity” between synthetic compounds and biological agents. Most of the synthetic compounds with low molecular weights around 500 can easily penetrate the cellular membrane and bind to intracellular molecular targets (Table 1). Their binding to the targeted molecule is not specific enough, which results in the elicitation of various off-target effects and consequently limits the administration dose. Therefore, the available dose variation of synthetic compounds is within several-fold in clinical practice except for glucocorticoids.

On the contrary, biological agents, typically immunoglobulin G antibodies with a molecular weight of ~150,000, are unable to penetrate the cellular membrane and only bind to the extracellular or membrane molecular targets. Also, their binding to the targeted molecule is highly specific. Therefore, biological agents can be dose-escalated until the sufficient neutralization of targeted molecules such as TNF.<sup>22)</sup> The serum trough level of biological agents correlates with the sufficiency of the neutralization of targeted molecules. Thus, monitoring the serum trough level of biological agents will be widely performed in the near future. It should be noted that the primary objective of the serum trough monitoring of biological agents is to avoid the lack of effectiveness due to underdosing, whereas that of synthetic compounds is to avoid dose-dependent adverse events due to overdosing.

## Conclusion

A fundamental understanding of the concept of disease activity as time-differentiated organ damage, mainly joint destruction, is crucial for the management of RA, and it may help the future development of more valid and suitable clinical measures of RA activity than those currently available.

**Conflicts of interest:** Non declared.

## References

- Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis.* 2016; 75: 3-15.
- Takeuchi T, Kameda H. The Japanese experience with biologic therapies for rheumatoid arthritis. *Nat Rev Rheumatol.* 2010; 6: 644-52.
- Ito H, Ogura T, Hirata A, Takenaka S, Mizushima K, Fujisawa Y, et al. Global assessments of disease activity are age-dependent determinant factors of clinical remission in rheumatoid arthritis. *Semin Arthritis Rheum.* 2017; 47: 310-4.
- Hirata A, Ogura T, Hayashi N, Takenaka S, Ito H, Mizushima K, et al. Concordance between patient-reported joint symptoms, physician-examined arthritic signs and ultrasound-detected synovitis in rheumatoid arthritis. *Arthritis Care Res.* 2017; 69: 801-6.
- Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. *Lancet.* 2004; 364: 263-9.
- Smolen JS, van der Heijde DMFM, St. Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab. Results from the ASPIRE trial. *Arthritis Rheum.* 2006; 54: 702-10.
- Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate. Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. *Arthritis Rheum.* 2006; 54: 3119-25.
- Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. *J Rheumatol.* 2009; 36: 1429-41.
- Ikeda K, Nakagomi D, Sanayama Y, Yamagata M, Okubo A, Iwamoto T, et al. Correlation of radiographic progression with the cumulative activity of synovitis estimated by power Doppler ultrasound in rheumatoid arthritis: difference between patients treated with methotrexate and those treated with biological agents. *J Rheumatol.* 2013; 40: 1967-76.
- Tsuji H, Yano K, Furu M, Yamakawa N, Ikari K, Hashimoto M, et al. Time-averaged disease activity fits better joint destruction in rheumatoid arthritis. *Sci Rep.* 2017; 7: 5856.
- Tugwell P, Boers M, D'Agostino MA, Beaton D, Boonen A, Bingham CO 3<sup>rd</sup>, et al. Updating the OMERACT filter: implications of filter 2.0 to select outcome instruments through assessment of “truth”: content, face, and construct validity. *J Rheumatol.* 2015; 41: 2460-4.
- Wells G, Beaton DE, Tugwell P, Boers M, Kirwan JR, Bingham CO 3<sup>rd</sup>, et al. Updating the OMERACT filter: discrimination and feasibility. *J Rheumatol.* 2014; 41: 1005-10.
- van der Heijde DM, van't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. *Ann Rheum Dis.* 1990; 49: 916-20.
- Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL, et al. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum.* 1995; 38: 44-8.
- Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. *Rheumatology.* 2003; 42: 244-57.
- Baker JF, Conaghan PG, Smolen JS, Aletaha D, Shults J, Emery P, et al. Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. *Arthritis Rheum.* 2014; 66: 794-802.
- Navarro-Compán V, Gherghe AM, Smolen JS, Aletaha D, Landewé R, van der Heijde D. Relationship between disease activity indices and their components and radiographic progression in RA: a systematic literature review. *Rheumatology.* 2015; 54: 994-1007.
- Kameda H, Sekiguchi N, Nagasawa H, Amano K, Takei H, Suzuki K, et al. Development and validation of the handy

- rheumatoid activity score with 38 joints (HRAS38) for rheumatoid arthritis in patients receiving infliximab. *Mod Rheumatol.* 2006; 16: 381-8.
- 19) Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, et al. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. *Mod Rheumatol.* 2010; 20: 531-8.
- 20) Kurasawa T, Nagasawa H, Kishimoto M, Amano K, Takeuchi T, Kameda H. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within two years after infliximab discontinuation in patients with rheumatoid arthritis: an open, randomized, controlled trial. *Mod Rheumatol.* 2014; 24: 561-6.
- 21) Kameda H, Kanbe K, Sato E, Ueki Y, Saito K, Nagaoka S, et al. A merged presentation of clinical and radiographic data using probability plots in a clinical trial, the JESMR study. *Ann Rheum Dis.* 2013; 72: 310-2.
- 22) Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate with rheumatoid arthritis: results from the RISING study. *Mod Rheumatol.* 2009; 19: 478-87.

---

**Hideto Kameda, Professor      Curriculum vitae**
Undergraduate

1985-1990      Keio University School of Medicine Tokyo, Japan (Medicine)

Graduate

1990-1994      Keio University School of Medicine, Tokyo, Japan (Internal Medicine)

Post Graduate

1997-2000      Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, National Institutes of Health, NC, USA

Academic

1994-1997      Instructor, Keio University Hospital, Tokyo, Japan

2000-2003      Instructor, Saitama Medical Center, Kawagoe, Japan

2003-2009      Assistant Professor, Saitama Medical Center, Kawagoe, Japan

2009-2013      Assistant Professor, School of Medicine, Keio University, Tokyo, Japan

2013-          Professor, Faculty of Medicine, Toho University, Tokyo, Japan

Specialty Certification

1996          Japanese Board of Internal Medicine

2002          Japanese Board of Rheumatology

2008          Japanese Board of Instructor of Rheumatology

**Academic Association Positions**

Director of the Japan Society for Clinical Immunology

Director of the Japan Spondyloarthritis Society

Auditor of the Japanese Society of Inflammation and Regeneration

Councilor of the Japan College of Rheumatology

Councilor of the Japanese Society of Internal Medicine

International Fellow of the American College of Rheumatology